|1.||Kim, Nam Keun: 5 articles (09/2010 - 05/2005)|
|2.||Tamura, T: 3 articles (05/2002 - 01/2000)|
|3.||Johanning, G L: 3 articles (05/2002 - 01/2000)|
|4.||Wenstrom, K D: 3 articles (05/2002 - 01/2000)|
|5.||Castro, Rita: 2 articles (07/2015 - 06/2009)|
|6.||Almeida, Sofia: 2 articles (07/2015 - 06/2009)|
|7.||Cascalheira, José F: 2 articles (07/2015 - 06/2009)|
|8.||Palmeira, Manuela: 2 articles (07/2015 - 06/2009)|
|9.||Domingues, Fernanda C: 2 articles (07/2015 - 06/2009)|
|10.||Ge, J: 2 articles (01/2015 - 07/2013)|
12/01/2011 - "The aim of the present study was to investigate hyperhomocysteinemia in Tunisian bipolar I patients according to 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism. "
10/01/2011 - "A recessively inherited defect leading to deficiency of the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) underlies one form of hyperhomocysteinemia. "
02/01/2005 - "Homozygosity for the thermolabile variant of 5,10-methylenetetrahydrofolate reductase (C677T) that causes hyperhomocysteinemia has been reported in 5-15% of general populations. "
07/01/2002 - "Mild hyperhomocysteinemia is associated with homozygosity for the thermolabile variant of 5,10-methylenetetrahydrofolate reductase (MTHFR) and could increase the risk of venous thromboembolic disease (VTD). "
12/01/1998 - "One of the important factors causing hyperhomocysteinemia is decrease of 5,10-Methylenetetrahydrofolate reductase. "
11/01/2014 - "The aim of this retrospective multicenter study was to assess the correlation between TS, 5,10-methylenetetrahydrofolate reductase (MTHFR) and excision repair cross-complementing group 1 (ERCC1) gene polymorphisms and the efficacy of pemetrexed-based first-line chemotherapy of mesothelioma patients. "
02/10/2014 - "Associations between 5,10-methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism and ischemic stroke have been reported (Ariyaratnam et al., 2007; Banerjee et al., 2007; Casas et al., 2004), but the results of these studies are inconsistent. "
01/01/2010 - "Previous studies have demonstrated that a common polymorphism in the gene encoding 5,10-methylenetetrahydrofolate reductase (MTHFR) is associated with an increased risk for stroke. "
06/01/2007 - "We compared 5,10-methylenetetrahydrofolate reductase genotypes in groups of subjects presenting ischemic stroke (n = 127) and normal control (n = 126) and found an odds ratio of 1.97 (95% CI, 0.84-4.64) in a multivariate analysis in which results were adjusted to baseline clinical characteristics of study participants. "
06/01/2007 - "A meta-analysis study suggested that the 5,10-methylenetetrahydrofolate reductase 677TT genotype might have a small influence in determining susceptibility to ischemic stroke. "
06/01/2007 - "We found that the homozygous 5,10-methylenetetrahydrofolate reductase C677T genotype was not a risk factor for ischemic stroke in these Brazilian subjects."
|4.||Neural Tube Defects (Exencephaly)
01/01/2014 - "This study aims to investigate the single nucleotide polymorphisms (SNPs) of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and neural tube defects (NTDs) in Chinese population. "
08/01/2007 - "There are several studies that have found a positive association between neural tube defects (NTDs) and the common mutation 677C > T of 5,10-methylenetetrahydrofolate reductase (MTHFR), and others that have not found such an association. "
03/01/2012 - "This metaanalysis suggests that 5,10-methylenetetrahydrofolate reductase A1298C polymorphism is not associated with neural tube defect susceptibility in the white population."
03/01/2012 - "The pooled results showed no significant association between 5,10-methylenetetrahydrofolate reductase A1298C polymorphism and neural tube defect susceptibility in any genetic contrast among the 3 groups, except 1 (AC vs AA in neural tube defect patients: odds ratio, 1.16; 95% CI, 1.10-1.32; P = .03), which, however, turned out to be of no statistical significance in the subgroup of the white population (odds ratio, 1.14; 95% CI, 0.98-1.31; P = .08). "
03/01/2012 - "To determine whether 5,10-methylenetetrahydrofolate reductase A1298C polymorphism is associated with neural tube defect susceptibility. "
12/01/2003 - "Tumors with aberrant DNA methylation of CpG islands within promoter regions of the hMLH1, TIMP3, and ARF genes also contained higher levels of both 5,10-methylenetetrahydrofolate and FH4. "
01/01/1998 - "Plasma drug levels and tumor, gut and marrow 5,10-methylenetetrahydrofolate were assayed. "
07/01/1988 - "In tumor tissue, 5,10-methylenetetrahydrofolate increased eight-fold two to four hours following the two-hour infusion and two-fold during the CI of dl-CF and FUra. "
09/01/2012 - "5,10-Methylenetetrahydrofolate reductase (MTHFR) polymorphisms implicated in the cancer development, but the published studies had yielded inconsistent results. "
07/01/1995 - "The study was terminated on the basis of results showing comparable 5,10-methylenetetrahydrofolate (mTHF) tumor- and tissue levels after administration of MTHF or FA."
|2.||Folic Acid (Vitamin M)
|6.||Glutathione Transferase (Glutathione S-Transferase)
|7.||5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase (Methyltetrahydrofolate Homocysteine Methyltransferase)
|8.||Prothrombin (Factor II)
|10.||Vitamin B 12 (Cyanocobalamin)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Hematopoietic Stem Cell Transplantation
|5.||Renal Dialysis (Hemodialysis)